Destiny Pharma PLC Result of AGM (7569A)

TIDMDEST

RNS Number : 7569A

Destiny Pharma PLC

03 June 2021

Destiny Pharma plc

("Destiny Pharma" or "the Company")

Result of Annual General Meeting

Brighton, United Kingdom - 3(rd) June 2021 - Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, announces that all resolutions proposed to shareholders at the Annual General Meeting held earlier today were duly passed.

The full text of each resolution was included in the notice of the meeting, which was made available on the Company's website and posted to shareholders on 4(th) May 2021. The results for the resolutions will shortly be available on the Investors section of the Company's website, www.destinypharma.com .

Nick Rodgers, Chairman of Destiny Pharma, commented :

"It has been a transformational last six months for Destiny Pharma. We recently delivered excellent Phase 2b data from our XF-73 nasal gel clinical study for the prevention of post-surgical infections and have now started talking to regulators regarding possible Phase 3 clinical plans . Also, we expanded our pipeline through the acquisition of NTCD-M3 to take it through its Phase 3 clinical study. NTCD-M3 has the potential to become the leading treatment for C. difficile infections, targeting a market that is forecast to grow to $1.7 billion by 2026. We remain committed to developing our novel products that prevent infections and look forward to delivering further progress and another successful year."

For further information, please contact:

Destiny Pharma plc

Neil Clark, CEO

Shaun Claydon, CFO

[phone]

[e-mail]

Optimum Strategic Communications

Mary Clark/ Shabnam Bashir/ Manel Mateus

[phone]

[e-mail]

finnCap Ltd (Nominated Advisor & Joint Broker)

Geoff Nash / Kate Bannatyne, Corporate Finance

Alice Lane, Corporate Broking

[phone]

WG Partners (Joint Broker)

Nigel Barnes / Claes Spång / Nigel Birks

[phone]

About Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COV, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects.

   For further information on the company, please visit   https://www.destinypharma.com 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGUORARAUUNRAR

(END) Dow Jones Newswires

June 03, 2021 07:03 ET (11:03 GMT)